Second, inhibiting CLK4 can address therapy resistance by disrupting splicing‐driven mechanisms, such as WT1 and dCK splicing abnormalities, which are associated with chemotherapy resistance in leukemia.[27] Third, CLK4 inhibitors may exhibit synergistic potential when combined with other treatments, such as chemotherapy or immunotherapy, enhancing therapeutic efficacy through complementary mechanisms. The gene discussed is DCK; the disease is leukemia.